NR3C2 and diabetic kidney disease: The SONAR, the CREDENCE and the FIDELIO-DKD trials are particularly relevant since they demonstrated that sodium-glucose co-transporter inhibitors (SGLT2is), endothelin-1 receptor antagonists (ERA) and the novel non-steroidal mineralocorticoid receptor antagonist (MRA) confer a reduction of risk of progression to ESKD in DKD patients already treated with RAASi.